TREM1 and neoplasm: An agonistic TREM1 monoclonal antibody (PY159) could upregulate the secretion of inflammatory factors such as IFN-γ, CCL3, CCL4, IL-8, and TNF and increased tumor sensitivity to anti-PD-1 therapy in syngeneic mouse tumor models19.